Supplementary Figures – Impact of fast-track regulatory designations on strategic commercialisation decisions for autologous cell therapies

figure

posted on 2022-01-25, 08:51 authored by Taylor & FrancisTaylor & Francis, Ching Lam, Edward Meinert, Aidong Yang, Zhanfeng Cui

Supplementary Material 2. Facility floor plan schematic

Supplementary Material 4. Forecasted demand level for products over 20 years. Dotted lines refer to the scenario with fast-track designations, solid lines refer to the scenario without fast-track designations.

Funding

CRMI Technology Centre at the University of Oxford

History

Usage metrics

Keywords

Autologous Cell Therapies Capacity Planning Drug Development Decisional Tool Optimisation Regulatory Medical and Health Sciences not elsewhere classified

Licence

CC BY-NC-ND 4.0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM